Prima Biomed Ltd. announced interim data from a phase I study of the TACTI-mel (Two ACTive Immunotherapeutics in melanoma) program on its most advanced pipeline candidate IMP321 (based on the LAG-3 immune control mechanism), for the treatment of patients with unresectable or metastatic melanoma.
The company’s shares surged 7.4% after the news. Prima’s year-to-date share price movement shows that the company has underperformed the Zacks classified Medical-Biomedical/Genetics industry. Specifically, the stock plunged almost 34.2% during this period, steeper than the industry’s declined of 26.1%.
The study evaluated IMP321, in combination with Merck & Co., Inc.’s (MRK - Free Report) PD-1 checkpoint inhibitor Keytruda, in patients with unresectable or metastatic melanoma who had suboptimal or no responses to Keytruda.
The Database Safety Monitoring Board (DSMB) confirmed that IMP321, in combination with Keytruda, was safe and well tolerated when dosed at 1 mg. Further, the DSMB approved the continuation of the dose escalation to the next level of 6 mg.
The company expects to read out additional data in terms of safety and activity throughout 2017.
IMP321 is also being evaluated, in combination with Celgene Corporation’s Abraxane, in a phase IIb chemo-immunotherapy study AIPAC (Active Immunotherapy PAClitaxel) for the treatment of metastatic breast cancer.
The company noted that many large pharmaceutical partners are developing LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer.
Prima currently carries a Zacks Rank #3 (Hold).
Key Pick in the Sector
Vanda Pharmaceuticals Inc. (VNDA - Free Report) is a better-ranked stock in the health care sector sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Vanda’s loss estimates for 2016 narrowed from 62 cents to 45 cents in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Prima Biomed Ltd. announced interim data from a phase I study of the TACTI-mel (Two ACTive Immunotherapeutics in melanoma) program on its most advanced pipeline candidate IMP321 (based on the LAG-3 immune control mechanism), for the treatment of patients with unresectable or metastatic melanoma.
The company’s shares surged 7.4% after the news. Prima’s year-to-date share price movement shows that the company has underperformed the Zacks classified Medical-Biomedical/Genetics industry. Specifically, the stock plunged almost 34.2% during this period, steeper than the industry’s declined of 26.1%.
The study evaluated IMP321, in combination with Merck & Co., Inc.’s (MRK - Free Report) PD-1 checkpoint inhibitor Keytruda, in patients with unresectable or metastatic melanoma who had suboptimal or no responses to Keytruda.
The Database Safety Monitoring Board (DSMB) confirmed that IMP321, in combination with Keytruda, was safe and well tolerated when dosed at 1 mg. Further, the DSMB approved the continuation of the dose escalation to the next level of 6 mg.
The company expects to read out additional data in terms of safety and activity throughout 2017.
IMP321 is also being evaluated, in combination with Celgene Corporation’s Abraxane, in a phase IIb chemo-immunotherapy study AIPAC (Active Immunotherapy PAClitaxel) for the treatment of metastatic breast cancer.
The company noted that many large pharmaceutical partners are developing LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer.
Prima currently carries a Zacks Rank #3 (Hold).
Key Pick in the Sector
Vanda Pharmaceuticals Inc. (VNDA - Free Report) is a better-ranked stock in the health care sector sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Vanda’s loss estimates for 2016 narrowed from 62 cents to 45 cents in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MRK - FREE
Get the latest research report on VNDA - FREE